Friday, August 28, 2026
FDA approves Moderna's updated 2026-2027 COVID vaccines
Moderna said on August 27 that the FDA approved the 2026-2027 formulas of Spikevax and mNEXSPIKE, both targeting the JN.1-lineage XFG subvariant of SARS-CoV-2. Spikevax is cleared for high-risk people aged 6 months through 64 and all adults 65 and older, while mNEXSPIKE is cleared for high-risk people aged 12 through 64 and all adults 65 and older; the company said the shots should be available in the coming days.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email flightatlas.contact@gmail.com and we will fix it.
/ Related
- Moderna to raise $2 billion in convertible senior notesThursday, August 27, 2026
- Moderna-Merck melanoma vaccine hits Phase 3 goals, shares surgeWednesday, August 19, 2026
- FDA approves Moderna's mFlusiva, the first mRNA flu vaccineMonday, August 17, 2026
- Moderna opens trial of combined RSV/hMPV shot for older adultsSaturday, August 15, 2026